Rwanda returnee operation

Document collected by the University of Texas Libraries from the web-site of the Reseau Documentaire International Sur La Region Des Grands Lacs Africains (International Documentation Network on the Great African Lakes Region). The Reseau distributes "gray literature", non-published or limited distribution government or NGO documents regarding the Great Lakes area of central Africa including Rwanda, Burundi, and the Democratic Republic of Congo.UT Librarie

Composition and evaluation of the lethality of Lippia gracilis essential oil to adults of Biomphalaria glabrata and larvae of Artemia salina

Lippia gracilis essential oil (LGEO) was evaluated for its molluscicidal activity against Biomphalaria glabrata and toxicity to brine shrimps (Artemia salina). L. gracilis was collected from the city Tomar do Gerú- Sergipe, Brazil. The LGEO were characterized by gas chromatography-mass spectrometry (GC/MS). The values of LC10, LC50 and LC90 were respectively 36.9, 62.2 and 82.8 ppm for B. glabrata and 19.6, 23.6 and 26.1 ppm for A. salina. GC/MS analysis showed a total volatile content of 98.6% in the LGEO. The major components were identified as thymol (24.0%), p-cymene (15.9%), methyl-thymol (11.7%), γ-terpinene (10.9%) and β-caryophyllene (7.8%).Keywords: Chemical composition, Lippia species, molluscicidal activity, Verbenacea

A novel risk factor associated with colonization by Carbapenemase-Producing Enterobacteriaceae: Use of Proton Pump Inhibitors in addition to Antimicrobial Treatment

published_or_final_versio

Assistance aux réfugiés en prevenance du Rwanda; services communautaires, Zaire-Goma (Nord-Kivu) du 18-04-94 au 30-06-94

Document collected by the University of Texas Libraries from the web-site of the Reseau Documentaire International Sur La Region Des Grands Lacs Africains (International Documentation Network on the Great African Lakes Region). The Reseau distributes "gray literature", non-published or limited distribution government or NGO documents regarding the Great Lakes area of central Africa including Rwanda, Burundi, and the Democratic Republic of Congo.UT Librarie

Analysis of the Ex Vivo and In Vivo Antiretroviral Activity of Gemcitabine

Replication of retroviral and host genomes requires ribonucleotide reductase to convert rNTPs to dNTPs, which are then used as substrates for DNA synthesis. Inhibition of ribonucleotide reductase by hydroxyurea (HU) has been previously used to treat cancers as well as HIV. However, the use of HU as an antiretroviral is limited by its associated toxicities such as myelosuppression and hepatotoxicity. In this study, we examined the ribonucleotide reductase inhibitor, gemcitabine, both in cell culture and in C57Bl/6 mice infected with LP-BM5 murine leukemia virus (LP-BM5 MuLV, a murine AIDS model). Gemcitabine decreased infectivity of MuLV in cell culture with an EC50 in the low nanomolar range with no detectable cytotoxicity. Similarly, gemcitabine significantly decreased disease progression in mice infected with LP-BM5. Specifically, gemcitabine treatment decreased spleen size, plasma IgM, and provirus levels compared to LP-BM5 MuLV infected, untreated mice. Gemcitabine efficacy was observed at doses as low as 1 mg/kg/day in the absence of toxicity. Higher doses of gemcitabine (3 mg/kg/day and higher) were associated with toxicity as determined by a loss in body mass. In summary, our findings demonstrate that gemcitabine has antiretroviral activity ex vivo and in vivo in the LP-BM5 MuLV model. These observations together with a recent ex vivo study with HIV-1[1], suggest that gemcitabine has broad antiretroviral activity and could be particularly useful in vivo when used in combination drug therapy

XAF1 as a modifier of p53 function and cancer susceptibility

Cancer risk is highly variable in carriers of the common TP53-R337H founder allele, possibly due to the influence of modifier genes. Whole-genome sequencing identified a variant in the tumor suppressor XAF1 (E134*/Glu134Ter/rs146752602) in a subset of R337H carriers. Haplotype-defining variants were verified in 203 patients with cancer, 582 relatives, and 42,438 newborns. The compound mutant haplotype was enriched in patients with cancer, conferring risk for sarcoma (P = 0.003) and subsequent malignancies (P = 0.006). Functional analyses demonstrated that wild-type XAF1 enhances transactivation of wild-type and hypomorphic TP53 variants, whereas XAF1-E134* is markedly attenuated in this activity. We propose that cosegregation of XAF1-E134* and TP53-R337H mutations leads to a more aggressive cancer phenotype than TP53-R337H alone, with implications for genetic counseling and clinical management of hypomorphic TP53 mutant carriers

Experimental Investigation of Induced Draft Deluged Plate-finned Heat Exchanger Bundles

Please help populate SUNScholar with the full text of SU research output. Also - should you need this item urgently, please send us the details and we will try to get hold of the full text as quick possible. E-mail to [email protected]. Thank you.IngenieursweseMeganiese & Megatroniese Ingenieurswes